Fubotv earnings beat by $0.10, revenue topped estimates
WARSAW, IN - Zimmer Biomet Holdings (NYSE:ZBH) reported second-quarter earnings that exceeded analyst expectations on Wednesday, as strong performance in its U.S. hip and knee portfolios and global S.E.T. business drove results. The medical device maker also raised its full-year earnings guidance.
Zimmer Biomet shares edged up 0.11% in after hours trading following the announcement.
The orthopedic device manufacturer posted adjusted earnings of $2.07 per share for the quarter ended June 30, beating analyst estimates of $1.98. Revenue rose 7.0% to $2.08 billion, slightly above the consensus estimate of $2.06 billion. On an organic constant currency basis, revenue increased 2.8% YoY.
"Our team delivered another solid quarter of growth, as our robust new product cycle drove significant acceleration in our U.S. Hips and Knees portfolios and continued strong growth in our global S.E.T. business," said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet.
The company’s U.S. sales increased 6.1% to $1.17 billion, while international sales rose 8.1% to $903.5 million. The S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic) segment was particularly strong, with sales jumping 17.3% to $550.6 million.
Looking ahead, Zimmer Biomet raised its full-year 2025 adjusted earnings guidance to between $8.10 and $8.30 per share, up from its previous forecast of $7.90 to $8.10, and above the analyst consensus of $7.99. The company also tightened its revenue growth outlook, now expecting 6.7% to 7.7% reported growth, compared to its earlier projection of 5.7% to 8.2%.
The company recently announced a definitive agreement to acquire Monogram Technologies, an AI-driven robotics company, which Tornos noted "marks a bold step forward in surgical robotics" and demonstrates the company’s "commitment to addressing the most meaningful challenges in healthcare."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.